Author + information
- Received October 17, 2007
- Revision received December 13, 2007
- Accepted January 21, 2008
- Published online May 20, 2008.
- Masahito Ogawa, BS⁎,
- Jun-ichi Suzuki, MD⁎,⁎ (, )
- Keiichi Hishikari, BS⁎,
- Kiyoshi Takayama, PhD⁎,
- Hiroyuki Tanaka, MD, PhD† and
- Mitsuaki Isobe, MD, PhD⁎
- ↵⁎Reprint requests and correspondence:
Dr. Jun-ichi Suzuki, Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519 Japan.
Objectives Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metalloproteinases (MMPs) regulation. However, little is known about the effect of CAM in heart transplantation via MMP-9. The purpose of this study was to clarify the role of MMPs regulated by CAM in the progression of rejection.
Background The MMPs are critical in the development of inflammation and tissue remodeling. The MMP-9 level is associated with the rejection of heart transplantation.
Methods We orally administered CAM into murine cardiac allograft recipients. Total allomismatch combination and class II mismatch combination were used for the analysis of graft survival, pathology and molecular.
Results Clarithromycin improved acute rejection judged by graft survival and by myocardial cell infiltrating area in a total allomismatch combination. The CAM-treated allografts showed affected expression of T-cells, macrophages, and MMP-9 in immunohistochemistry. Zymography indicated that enhanced MMPs activities were observed in nontreated hearts, whereas CAM suppressed the levels. In chronic rejection, CAM suppressed the development of graft arterial disease and myocardial remodeling compared with that of nontreatment. Clarithromycin inhibited the expression of MMP-9, whereas the treatment did not alter the expression of MMP-2 and tissue inhibitor metalloproteinase-1 in macrophages and smooth muscle cells. Inhibition of MMP-9 by CAM was associated with suppression of smooth muscle cell migration and proliferation.
Conclusions Clarithromycin is useful to suppress allograft remodeling, because it is critically involved in the prevention of cardiac rejection through the suppression of MMP-9.
This work was supported by grants from the Japan Cardiovascular Research Foundation, a Grant-in-aid from the Japanese Ministry of Education, Science and Culture, a Grant-in-aid from the Japanese Ministry of Welfare, and the Organization for Pharmaceutical Safety and Research.
- Received October 17, 2007.
- Revision received December 13, 2007.
- Accepted January 21, 2008.
- American College of Cardiology Foundation